Sickle Cell EmergenciesFrom December 2018, Clots and OCP's
1 in 5000 Americans has sickle cell disease, and these patients are at high risk for a variety of complications. Mizuho sits down with Jessica Osterman and Katie Harter to discuss sickle cell disease, pain crisis and emergencies.21min 48Katherine Harter, MD, Jess Osterman, MD, and Mizuho Spangler, DO
Clots and OCPsFrom December 2018, Clots and OCP's
Our listeners are always asking for more Hematology content. They are also always asking for more Ob/Gyn content! In this segment, Neda and Rob address the two together with a few cases featuring both hypercoagulability and contraception.10min 23Rob Orman, MD and Neda Frayha, MD
Superficial ThrombophlebitisFrom November 2018, Those Clots are So Superficial
When PC RAP listener Lisa wrote us that she’s observed different clinicians manage superficial thrombophlebitis in lots of different ways, from doing absolutely nothing to serial ultrasound to anticoagulation, our own Rob Orman couldn’t wait to put his love of hematology to use. In this segment, he …11min 25Rob Orman, MD and Neda Frayha, MD
Anticoagulation with the DOACsFrom October 2018, My Pancreas is Necrosing!
It’s time for Hematology Rounds with Dr. Tom DeLoughery! In this segment, he and our own Matt DeClerck review the indications for and potential benefits and pitfalls of the direct oral anticoagulants (DOACs).31min 9Tom Deloughery, MD and Matthieu DeClerck, MD
Paper Chase #4 | Ferrous Sulfate vs Iron Polysaccharide Complex in Kids with IDAFrom April 2018, Will You Be My Facebook Friend?
Ferrous sulfate led to a greater increase in hemoglobin concentration at 12 weeks and higher rates of resolution of iron-deficiency anemia compared with iron polysaccharide complex. Good old, tried-and-true ferrous sulfate for the win.5min 34Andrew Buelt, DO and Joe Weatherly, DO
DOACs for VTE in Cancer - Tom DeLoughery for the Win!From March 2018, DOACs for VTE in Cancer - Tom DeLoughery for the Win!
Tom DeLoughery predicted a new practice pattern in an earlier PC RAP and he turned out to be totally right, so we’re proud to say “you heard it here first.”5min 28Andrew Buelt, DO
Cancer & ThrombosisFrom February 2018, The Tragically Sore Hip
Tom Deloughery shares his wisdom on all things cancer and thrombosis. First, he reviews why patients with cancer are more likely to have clots, then reviews some aspects of thrombosis that are unique to this population. Lastly, he discusses treatment standards, nuances and controversies.18min 54Tom Deloughery, MD and Matthieu DeClerck, MD
The COMPASS TrialFrom February 2018, The Tragically Sore Hip
This branch of the COMPASS trial examined 3 anticoagulation strategies in patients with “stable atherosclerotic disease”: rivaroxaban 5mg BID, ASA 100mg od + placebo BID, ASA 100 BID + rivaroxaban 2.5 mg BID. Casey’s analysis focused on the ASA groups, not the NOAC alone group. He concludes that …13min 36Casey Parker, MD
Hematology Rounds - ThrombocytopeniaFrom November 2017, Lytes and Bites
Dr. Deloughery reviews his approach to the incidental thrombocytopenia. He reviews the differential in sick and well appearing pt. He describes the major causes of thrombocytopenia and suggests a stepwise approach to evaluation.14min 29Tom Deloughery, MD and Heidi James, MD
The Tools of Satan: IVC FiltersFrom October 2017, It's Bloody Halloween!
More and more research is showing that inferior vena cava filters may just be the Tools of Satan. At least Hematologist Tom Deloughery thinks. In this chapter, Tom and Heidi discuss a recent article on the diminishing role of IVC filters in thrombosis management.16min 30Tom Deloughery, MD and Heidi James, MD
Thrombosis in Transgendered MedicineFrom September 2017, You Can Do It!!
Dr. Deloughery (The Delorean as I like to call him) is back, and this time he’s reviewing what we know about thrombosis risk in transgendered patients on hormone therapy. Transgendered medicine as a discipline has grown exponentially in the past decade, but the hematologic consequences are still …16min 8Tom Deloughery, MD and Heidi James, MD
Things I Do But Should I: WarfarinFrom November 2016, Aspirin Loses Its Tenure
In this chapter of things I do but should I: A patient with low INR, to bridge or not to bridge with heparin; How often should patients with stable INR be monitored; what’s the proper warfarin starting dose; when starting warfarin, do we need to bridge with heparin until the INR is therapeutic? •16min 44Vanessa Cardy, MD and Adrien Selim, MD
Things I do But Should I: Fecal Occult Blood TestingFrom October 2016, Running Toward Longevity
Discuss evidence based dietary and medication restrictions prior to fecal occult blood testing, based on the article by Konrad, Gerald, and Alan Katz. "Are medication restrictions before FOBT necessary? Practical advice based on a systematic review of the literature." Canadian Family Physician 58.9 …13min 15Vanessa Cardy, MD and Adrien Selim, MD
Lead PoisoningFrom September 2016, Best Weight, Best Exercise!
From the Festival of Saturn in ancient Rome to the water supply in Flint, Michigan, lead toxicity has been a scourge of humanity for millennia. •18min 9Stuart Swadron, MD FAAEM, Sean Nordt, MD PharmD FAAEM, and Rob Orman, MD
Anemia Deep Dive: MacrocytosisFrom August 2016, Feeling Restless
The final stop on our anemia deep dive. When the MCV gets over 100, it’s time to start looking for pathology.21min 17Tom Deloughery, MD and Rob Orman, MD
The Hemolytic AnemiasFrom June 2016, C Diff Shows No Mercy!
Sometimes an email isn't a problem of making blood, it;s a problem of breaking blood. •19min 3Tom Deloughery, MD and Rob Orman, MD
Paper Chase 1: GI Bleed and Anticoagulation Therapy for Those With A-FibFrom May 2016, The Sexology of Radicular Back Pain
Is it safe to restart warfarin after a GI bleed?7min 14Andrew Buelt, DO and Joe Weatherly, DO
Anemia Deep Dive Part 1: The CBC and Microcytic AnemiasFrom May 2016, The Sexology of Radicular Back Pain
The first part in a series on a dermatologist's approach to pretty much every type of anemia. •18min 26Rob Orman, MD and Tom Deloughery, MD
Hypogonadism Pt 2: Initiating Treatment, Risks of Therapy, Monitoring PatientsFrom March 2016, Where Has All The Testosterone Gone?
Obese patients with low testosterone may get significant benefit from weight loss.19min 14Joe Weatherly, DO and Margaret Wierman, MD
Hypogonadism Part 1: DiagnosisFrom March 2016, Where Has All The Testosterone Gone?
‘Low T’ by itself is not an indication for testosterone supplementation.17min 24Margaret Wierman, MD and Andrew Buelt, DO
‹ PreviousNext ›